Our scientific efforts are aimed at developing a macrolide, called Cethromycin, for new use as a treatment for several diseases where it has significant potential to provide valuable new treatments. Initially, we will focus on malaria – both as a therapeutic for radical cure of dormant recurring malaria and as a prophylactic for malaria prevention. Subsequently, we will develop the compound for the treatment of tick-borne diseases such as severe babesiosis, as well as bacterial infections where current antibiotics are failing due to resistance, such as sexually transmitted diseases like Chlamydia and Mycoplasma, bioterror microbes like anthrax and atypical respiratory bacteria like Legionella or Mycobacterium.